Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. For this purpose, Takis offers cutting-edge technologies and works with the idea that new cancer treatment must be based on in-depth knowledge of tumour biology and the concept of personalized cancer therapy. Together with some of its partners, Takis is involved in the identification of new biomarkers and in the development of molecular diagnostic tests. The main competence of Takis’ researchers is the delivery of genes in vivo through numerous technologies. The foremost one is the electric transfer of genes (gene-electro-transfer–EGT) on which we have more than ten years experience. This technology can significantly increase the tissue uptake of nucleic acids in vivo, such as skeletal muscle, or the tumor itself, with a functional enhancement that leads to relevant immunological and antitumoral effects. In this regard, In addition to its research pipeline, Takis is engaged with academic and industrial partners in research aimed at studying the effectiveness of innovative drugs in biological systems or develop diagnostic tests based on the detection of new biomarkers. Takis offers itself as partner of choice because of its efficiency, speed of execution and low operating costs.